Bevacizumab for recurrent hemangioendothelioma

Acta Oncol. 2011 Jan;50(1):153-4. doi: 10.3109/0284186X.2010.498829. Epub 2010 Oct 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Fractures, Spontaneous / etiology
  • Fractures, Spontaneous / surgery
  • Hemangioendothelioma, Epithelioid / drug therapy*
  • Hemangioendothelioma, Epithelioid / pathology
  • Hemangioendothelioma, Epithelioid / surgery
  • Humans
  • Laminectomy
  • Lumbar Vertebrae / pathology
  • Lumbar Vertebrae / surgery
  • Magnetic Resonance Imaging
  • Neoplasm Recurrence, Local / drug therapy*
  • Spinal Fusion
  • Spinal Neoplasms / complications
  • Spinal Neoplasms / drug therapy*
  • Spinal Neoplasms / pathology
  • Spinal Neoplasms / surgery
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab